Rong Zhiyuan, Liu Jiangwei, Cheng Weilun, Yansong Liu, Duan Yunqiang, Hu Anbang, Wang Xuelian, Zhang Jiarui, Zhang Hanyu, Li Yanling, Li Mingcui, S Shakila Suborna, Shang Yuhang, Fang Zhengbo, Kong Fanjing, Cui Delong, Chen Yulin, Ji Yuanhao, Ma Fei, Guo Baoliang
Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Nutr Cancer. 2025 Sep 17:1-11. doi: 10.1080/01635581.2025.2559436.
Previous studies have reported that both inflammation and nutrition may affect breast cancer development, but there has been no comprehensive analysis of the influence of the immune nutritional indicator Prognostic Nutritional Index on breast cancer. The Prognostic Nutritional Index (PNI), integrating serum albumin and lymphocyte count, serves as a dual biomarker reflecting systemic nutritional status and antitumor immune competence. Mechanistically, hypoalbuminemia signifies malnutrition and cancer-associated chronic inflammation, while lymphocytopenia indicates impaired immune surveillance facilitating tumor evasion. Clinically validated across gastrointestinal and breast malignancies, low PNI correlates with therapeutic resistance and reduced survival, attributable to compromised tissue repair and antitumor immunity. Despite its cost-effectiveness and calculability from routine blood tests, PNI's potential as an accessible risk stratification tool remains.
We selected 18,709 eligible participants from the National Health and Nutrition Examination Survey (NHANES) conducted from 2001-2018. Statistical methods such as weighted multivariate logistic regression and subgroup analysis were used to analyze the associations between the PNI and breast cancer incidence. In addition, the PNI thresholds for breast cancer incidence were determined a two-stage linear regression model. Finally, a machine learning algorithm (XGBoost) was applied to verify the effect of the PNI on the incidence of breast cancer. The Prognostic Nutritional Index (PNI), derived from serum albumin (ALB, g/L) and peripheral blood lymphocyte count (×10/L) the formula PNI = ALB + 5 × lymphocyte count, was evaluated using weighted multivariable logistic regression to assess its dose-response relationship with the outcome. To this end, PNI was modeled both as a continuous variable (per 1-unit increase) and using gender-specific tertiles (T1: <46.8; T2: 46.8-52.4; T3: >52.4).
In this study, the Prognostic Nutritional Index (PNI) demonstrated a significant inverse association with breast cancer risk. The mean PNI value was 52.5 (±8.9) in the overall population, with significantly lower values observed in breast cancer patients compared to controls ( < 0.001). A consistent dose-response relationship was identified, wherein each unit increase in PNI corresponded to a 4% reduction in breast cancer risk (fully adjusted OR = 0.96; 95% CI: 0.94-0.98). This linear association was further confirmed by restricted cubic splines (RCS) analysis (-overall <0.001; -non-linear > 0.05). Moreover, when PNI was categorized into tertiles, the highest tertile was associated with a substantially lower risk of breast cancer compared to the lowest tertile (OR = 0.58; 95% CI: 0.41-0.81; < 0.001). A two-stage linear regression model identified a PNI threshold of 58.0 for breast cancer incidence. Importantly, the relevance of PNI was corroborated by machine learning approaches; XGBoost algorithm identified PNI as one of the top five predictive variables for breast cancer. In conclusion, these findings indicate that lower PNI levels are significantly associated with increased breast cancer risk, highlighting its potential role as an auxiliary indicator for risk stratification. However, further prospective studies are warranted to validate its clinical utility.
Our study suggests that the PNI is negatively and linearly correlated with the incidence of breast cancer. A lower Prognostic Nutritional Index (PNI) is associated with an increased risk of breast cancer.
既往研究报道炎症和营养状况均可能影响乳腺癌的发生发展,但尚未对免疫营养指标预后营养指数(Prognostic Nutritional Index,PNI)对乳腺癌的影响进行全面分析。PNI综合血清白蛋白和淋巴细胞计数,是反映全身营养状况和抗肿瘤免疫能力的双重生物标志物。从机制上讲,低白蛋白血症意味着营养不良和癌症相关的慢性炎症,而淋巴细胞减少表明免疫监视受损,有利于肿瘤逃逸。在胃肠道和乳腺恶性肿瘤中均得到临床验证,低PNI与治疗抵抗和生存率降低相关,这归因于组织修复和抗肿瘤免疫受损。尽管PNI具有成本效益且可通过常规血液检测计算得出,但其作为一种易于获取的风险分层工具的潜力仍有待挖掘。
我们从2001年至2018年进行的美国国家健康与营养检查调查(National Health and Nutrition Examination Survey,NHANES)中选取了18,709名符合条件的参与者。采用加权多变量逻辑回归和亚组分析等统计方法分析PNI与乳腺癌发病率之间的关联。此外,采用两阶段线性回归模型确定乳腺癌发病率的PNI阈值。最后,应用机器学习算法(XGBoost)验证PNI对乳腺癌发病率的影响。预后营养指数(PNI)由血清白蛋白(ALB,g/L)和外周血淋巴细胞计数(×10/L)通过公式PNI = ALB + 5×淋巴细胞计数得出,采用加权多变量逻辑回归评估其与结局的剂量反应关系。为此,PNI既被建模为连续变量(每增加1个单位),也根据性别分为三分位数(T1:<46.8;T2:46.8 - 52.4;T3:>52.4)。
在本研究中,预后营养指数(PNI)与乳腺癌风险呈显著负相关。总体人群的平均PNI值为52.5(±8.9),与对照组相比,乳腺癌患者的PNI值显著更低(<0.001)。确定了一致的剂量反应关系,即PNI每增加1个单位,乳腺癌风险降低4%(完全调整后的OR = 0.96;95%CI:0.94 - 0.98)。受限立方样条(RCS)分析进一步证实了这种线性关联(-总体<0.001;-非线性>0.05)。此外,当将PNI分为三分位数时,与最低三分位数相比,最高三分位数与乳腺癌风险显著降低相关(OR = 0.58;95%CI:0.41 - 0.81;<0.001)。两阶段线性回归模型确定乳腺癌发病率的PNI阈值为58.0。重要的是,机器学习方法证实了PNI的相关性;XGBoost算法将PNI确定为乳腺癌的前五大预测变量之一。总之,这些发现表明较低的PNI水平与乳腺癌风险增加显著相关,突出了其作为风险分层辅助指标的潜在作用。然而,需要进一步的前瞻性研究来验证其临床实用性。
我们的研究表明PNI与乳腺癌发病率呈负相关且呈线性关系。较低的预后营养指数(PNI)与乳腺癌风险增加相关。